Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660732 · ClinicalTrials.gov registry record · Phase 2
Rilonacept in Subjects With Cardiac Sarcoidosis
A Phase 2 study of Cardiac Sarcoidosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT06660732 is a Phase 2 study of Cardiac Sarcoidosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 83-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (28% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06660732, a Phase 2 study of Cardiac Sarcoidosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
Conditions Studied
Interventions
- DRUG Rilonacept
Study Locations (2)
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660732
The ClinicalTrials.gov registry entry for NCT06660732 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (28% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Rilonacept is the first listed.
NCT06660732 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06660732 about?
NCT06660732 is a clinical study titled "Rilonacept in Subjects With Cardiac Sarcoidosis". The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
What is the current status of trial NCT06660732?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-05. Estimated completion is 2027-03.
What conditions does trial NCT06660732 study?
This clinical trial studies the following conditions: Cardiac Sarcoidosis.
What interventions are being tested in trial NCT06660732?
The interventions under investigation include: Rilonacept (DRUG).
Who is sponsoring clinical trial NCT06660732?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660732 being conducted?
This trial has 2 study locations across Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.